Title: Experimental Drug Slows Decline among Alzheimer’s Patients

Content: <div id='article-page'><div id='article-content' data-media-url='//news-app-staging.s3.amazonaws.com' data-base-url='//news-app-staging.herokuapp.com' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/A6.wav' data-capture-url='//staging.analytics.lingraphica.com/events/capture_news' data-article-title='Experimental Drug Slows Decline among Alzheimers Patients' data-article-id='6258'><script src='//news-app-staging.herokuapp.com/javascripts/getscripts.js'></script><link rel='stylesheet' href='//news-app-staging.herokuapp.com/stylesheets/article.css' type='text/css' /><div class='article'><p><span data-start-time='0' data-end-time='14979'>Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer&rsquo;s disease in a large human study the companies did.</span> <span data-start-time='14979' data-end-time='26771'>The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease.</span> <span data-start-time='26771' data-end-time='41438'>The companies said early results showed that the treatment reduced cognitive loss by 27 percent when compared to a placebo, an inactive substance. </span> <span data-start-time='41438' data-end-time='48229'>The 18-month-long study involved 1,800 subjects. </span> <span data-start-time='48229' data-end-time='53792'>All had been identified with early-stage Alzheimer&rsquo;s. </span> <span data-start-time='53792' data-end-time='65833'>The patients were measured for mental decline and their ability to do daily activities like putting on clothes and feeding themselves.</span> <span data-start-time='65833' data-end-time='78500'>Dr. Jeff Cummings is the director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada Las Vegas. </span> <span data-start-time='78500' data-end-time='87583'>The expert told Reuters, If you can slow a disease by almost 30 percent, that's fantastic.</span> <span data-start-time='87583' data-end-time='92479'>Expert Ronald Petersen also praised the findings. </span> <span data-start-time='92479' data-end-time='97792'>It's not a huge effect, but it's a positive effect, he said. </span> <span data-start-time='97792' data-end-time='106292'>Peterson directs the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota.</span> <span data-start-time='106292' data-end-time='117729'>A statement from the Alzheimer&rsquo;s Association called the findings the most hopeful to date for possible treatments of the disease causes.</span> <span data-start-time='117729' data-end-time='125479'>Eisai said it would discuss the full results from the study in late November. </span> <span data-start-time='125479' data-end-time='130604'>It also plans to publish findings in a medical publication. </span> <span data-start-time='130604' data-end-time='141646'>And the company said it is seeking quick approval for the drug in the United States, Japan and Europe by early next year.</span> </p></div><div class='control-buttons-sticky' style='display:none;'><div class='control-buttons'><button title='Back' class='back' disabled='disabled'></button><button title='Play' class='play' disabled='disabled'></button><button title='Pause' class='pause' style='display:none;'></button><button title='Forward' class='forward' disabled='disabled'></button><button class='finished-reading' style='display:none;'>Done</button></div></div></div><div id='article-media'><div id='media-image'><img src='https://news-app-production.s3.amazonaws.com/articles/5655/A6.jpeg'/></div></div><div id='question-content' style='display:none;'><div class='vocabulary_question question-container' data-question-id=18944 data-hint-location='53792' style='display:none;'><div class='question' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/which_of_the_following_is_a_definition_of_the_word_decline.wav'>Which of the following is a definition of the word decline?</div><div class='choices' data-correct-choice='to become worse'><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/to_become_worse.wav'><span>to become worse</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/to_become_better.wav'><span>to become better</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/to_stay_the_same.wav'><span>to stay the same</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/to_turn_to_metal.wav'><span>to turn to metal</span></div></div></div><div class='multiple_choice_question question-container' data-question-id=18945 data-hint-location='41438' style='display:none;'><div class='question' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/how_many_months_did_the_study_last.wav'>How many months did the study last?</div><div class='choices' data-correct-choice='18 months'><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/80_months.wav'><span>80 months</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/18_months.wav'><span>18 months</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/19_months.wav'><span>19 months</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/8_months.wav'><span>8 months</span></div></div></div><div class='sentence_completion_question question-container' data-question-id=18946 data-hint-location='14979' style='display:none;'><div class='question' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/the_results_could_mean_a_rare__blank__in_a_field_filled_with_failed_experiments_to_find_an_effective_treatment_for_the_disease.wav'>The results could mean a rare <span class='blank'>victory</span> in a field filled with failed experiments to find an effective treatment for the disease.</div><div class='choices' data-correct-choice='victory'><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/volume.wav'><span>volume</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/village.wav'><span>village</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/viscous.wav'><span>viscous</span></div><div class='choice' data-sound-name='https://news-app-production.s3.amazonaws.com/articles/5655/victory.wav'><span>victory</span></div></div></div><div class='question-buttons'><button class='skip-button'></button><button class='hint-button'></button><button class='speak-button'></button></div></div></div>

Sound Name: https://news-app-production.s3.amazonaws.com/articles/5655/A6.wav

Preview

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did. The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease. The companies said early results showed that the treatment reduced cognitive loss by 27 percent when compared to a placebo, an inactive substance. The 18-month-long study involved 1,800 subjects. All had been identified with early-stage Alzheimer’s. The patients were measured for mental decline and their ability to do daily activities like putting on clothes and feeding themselves. Dr. Jeff Cummings is the director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada Las Vegas. The expert told Reuters, If you can slow a disease by almost 30 percent, that's fantastic. Expert Ronald Petersen also praised the findings. It's not a huge effect, but it's a positive effect, he said. Peterson directs the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota. A statement from the Alzheimer’s Association called the findings the most hopeful to date for possible treatments of the disease causes. Eisai said it would discuss the full results from the study in late November. It also plans to publish findings in a medical publication. And the company said it is seeking quick approval for the drug in the United States, Japan and Europe by early next year.

Edit | Back